Cargando…

Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma Incorporating Hematological Biomarkers

PURPOSE: This study aimed to develop a nomogram for predicting pathologic complete response (pCR) after neoadjuvant chemoradiotherapy (CRT) in patients with esophageal squamous cell carcinoma (ESCC) by integrating hematological biomarkers and clinicopathological characteristics. MATERIALS AND METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Yingjia, Chen, Jinbin, Zhao, Lei, Li, Qiaoqiao, Zhu, Jinhan, Yang, Hong, Guo, Suping, Xi, Mian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812014/ https://www.ncbi.nlm.nih.gov/pubmed/32898941 http://dx.doi.org/10.4143/crt.2020.594

Ejemplares similares

Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma
por: Wen, Jing, et al.
Publicado: (2022)

Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma
por: Huang, Ren-Wen, et al.
Publicado: (2014)

Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2018)

A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901)
por: Chen, Rui, et al.
Publicado: (2023)

Addendum: Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2022)

CT-based deep learning radiomics and hematological biomarkers in the assessment of pathological complete response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma: A two-center study
por: Zhang, Meng, et al.
Publicado: (2023)

Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: a randomized phase II trial
por: Liu, Shiliang, et al.
Publicado: (2021)

Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma
por: Xu, Lei, et al.
Publicado: (2022)

Predicting Prognosis and Adverse Events by Hematologic Markers in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy
por: Cai, Guoxin, et al.
Publicado: (2020)

Association of Sialic Acid–Binding Immunoglobulin-Like Lectin 15 With Phenotypes in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Chemoradiotherapy
por: Zhou, Sha, et al.
Publicado: (2023)

TNM Staging Matched-pair Comparison of Surgery After Neoadjuvant Chemoradiotherapy, Surgery Alone and Definitive Chemoradiotherapy for Thoracic Esophageal Squamous Cell Carcinoma
por: Liu, ShiLiang, et al.
Publicado: (2017)

Indoleamine 2,3-dioxygenase 1 and Programmed Cell Death-ligand 1 Co-expression Predicts Poor Pathologic Response and Recurrence in Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy
por: Zhou, Sha, et al.
Publicado: (2019)

Neoadjuvant chemoradiotherapy with camrelizumab in patients with locally advanced esophageal squamous cell carcinoma
por: Chen, Fei, et al.
Publicado: (2022)

Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy
por: Chi, Dongmei, et al.
Publicado: (2021)

Comparative Outcomes of Induction Chemotherapy Followed By Definitive Chemoradiotherapy versus Chemoradiotherapy Alone In Esophageal Squamous Cell Carcinoma
por: Luo, Li-Ling, et al.
Publicado: (2017)

CT-based radiomic signatures for prediction of pathologic complete response in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy
por: Yang, Zhining, et al.
Publicado: (2019)

NEOADJUVANT CHEMORADIOTHERAPY FOLLOWED BY TRANSHITAL ESOPHAGECTOMY IN LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: IMPACT OF PATHOLOGICAL COMPLETE RESPONSE
por: ALVES, Iuri Pedreira Fillardi, et al.
Publicado: (2021)

Prediction of pathological response grading for esophageal squamous carcinoma after neoadjuvant chemoradiotherapy based on MRI imaging using PDX
por: Shi, Jingzhen, et al.
Publicado: (2023)

Recent Advances in Combination of Immunotherapy and Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
por: Wang, Ruixi, et al.
Publicado: (2022)

Sensitivity value of hematological markers in patients receiving chemoradiotherapy for esophageal squamous cell carcinoma
por: Zhu, Shan, et al.
Publicado: (2016)

Impact of Radiation Dose on Survival for Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Chemoradiotherapy
por: Yang, Yang, et al.
Publicado: (2020)

Association Between Lymphopenia and Survival Outcomes in Esophageal Carcinoma Patients Receiving Combined Immunotherapy and Chemoradiotherapy
por: Cheng, Xingyuan, et al.
Publicado: (2023)

An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma
por: Zhang, Chaoqi, et al.
Publicado: (2020)

A three‐lncRNA signature of pretreatment biopsies predicts pathological response and outcome in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy
por: Zhang, Chaoqi, et al.
Publicado: (2020)

Characteristics and Treatment of Brain Metastases from Esophageal Squamous Cell Carcinoma
por: Li, Qiaoqiao, et al.
Publicado: (2018)

Neoadjuvant vs definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma patients
por: Chen, Chih-Yi, et al.
Publicado: (2018)

Neoadjuvant chemoradiotherapy plus surgery in the treatment of potentially resectable thoracic esophageal squamous cell carcinoma
por: Yan, Mao-Hui, et al.
Publicado: (2020)

Predictive Value of Endoscopic Observations and Biopsy After Neoadjuvant Chemoradiotherapy in Assessing the Pathologic Complete Response of Patients With Esophageal Squamous Cell Carcinoma
por: Taghizadeh Kermani, Ali, et al.
Publicado: (2022)

Trafficking protein TMED3 promotes esophageal squamous cell carcinoma
por: Yang, Yuxian, et al.
Publicado: (2023)

Neoadjuvant chemoradiotherapy followed by esophagectomy vs. surgery alone in the treatment of resectable esophageal squamous cell carcinoma
por: FUJIWARA, YOSHINORI, et al.
Publicado: (2013)

Patterns and timing of recurrence in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy plus esophagectomy
por: Nagaki, Yushi, et al.
Publicado: (2021)

A Survival Prediction Nomogram for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery
por: Ding, Tianyan, et al.
Publicado: (2021)

Moderately differentiated esophageal squamous cell carcinoma has a poor prognosis after neoadjuvant chemoradiotherapy
por: He, Wenwu, et al.
Publicado: (2021)

The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma
por: Park, Seong Yong, et al.
Publicado: (2020)

Effect of circumferential resection margin status on survival and recurrence in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy
por: Gu, Yi-Min, et al.
Publicado: (2022)

The Role of Adjuvant Chemotherapy after Neoadjuvant Chemoradiotherapy Followed by Surgery in Patients with Esophageal Squamous Cell Carcinoma
por: Park, Seong Yong, et al.
Publicado: (2023)

Is There a Benefit in Receiving Concurrent Chemoradiotherapy for Elderly Patients with Inoperable Thoracic Esophageal Squamous Cell Carcinoma?
por: Zhang, Peng, et al.
Publicado: (2014)

Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trial
por: Jiang, Hui, et al.
Publicado: (2023)

Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for esophageal squamous cell cancer: A meta-analysis
por: Guo, Yaru, et al.
Publicado: (2022)

Adjuvant Chemoradiotherapy Associated with Improved Overall Survival in Resected Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy in Intensity-Modulated Radiotherapy Era
por: Yap, Wing-Keen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_btti7bnigpsmb0a1ij2el2vbj6